premise: GlaxoSmithKline is nearing a deal to acquire Stiefel Laboratories, a large maker of dermatology products, for as much as $3 billion, people with knowledge of the talks said Sunday. These people cautioned that the talks were continuing and could still fall apart. If a deal is reached, it would be the latest round of consolidation among drug makers, who have sought to acquire product lines in the face of pressure from rivals making generic products. So far this year, Pfizer agreed to buy Wyeth for $68 billion; Merck agreed to acquire Schering-Plough for $41 billion; and Roche struck a $46.8 billion deal for the 44 percent of Genentech it did not already own.
hypothesis: GlaxoSmithKline is a British drug company.